DK2729482T3 - Fremgangsmåde til oprensning af fc-fusionsprotein - Google Patents
Fremgangsmåde til oprensning af fc-fusionsprotein Download PDFInfo
- Publication number
- DK2729482T3 DK2729482T3 DK12811874.2T DK12811874T DK2729482T3 DK 2729482 T3 DK2729482 T3 DK 2729482T3 DK 12811874 T DK12811874 T DK 12811874T DK 2729482 T3 DK2729482 T3 DK 2729482T3
- Authority
- DK
- Denmark
- Prior art keywords
- protein
- chromatography
- fusion protein
- product
- resin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
Claims (15)
- FREMGANGSMÅDE TIL OPRENSNING AF FC-FUSIONSPROTEIN1. Fremgangsmåde til oprensning af et Fc-fusionsprotein fra én eller flere urenheder i en prøve, hvilken fremgangsmåde omfatter følgende trin: a) tilvejebringelse af en prøve, der omfatter et Fc-fusionsprotein, der er produceret i et eukaryotisk ekspressionssystem; b) binding af det Fc-fusionsprotein, der er til stede i prøven, til en Protein A affinitetskromatografiharpiks; c) eluering af Fc-fusionsproteinet fra Protein A-harpiksen ved anvendelse af en gradient af 50 mM citrat pH 5,0 til 100 mM citrat pH 4,0, hvor det eluerede produkt tilvejebringer en anden prøve, eventuelt henvist til som et Protein A-PRODUKT (PAP); d) binding af PAP’et til en kationbytter- (CEX) kromatografiharpiks; e) eluering af den anden prøve fra CEX-harpiksen med en 25 mM natriumphosphatbuffer, pH 4,0, der omfatter 25 mM arginin, som en lineær ionisk styrkegradient, hvor det eluerede produkt tilvejebringer en tredje prøve, eventuelt henvist til som et CEX-Produkt (CEXP); f) binding CEXP’et til en anionbytter- (AEX) kromatografiharpiks; og g) eluering af den tredje prøve fra AEX-harpiksen, hvor det eluerede produkt tilvejebringer en oprenset F c-fusionspro teinsammensætning.
- 2. Fremgangsmåde ifølge krav 1, hvor Fc-fusionsproteinet er p75 TNFR:Fc.
- 3. Fremgangsmåde ifølge krav 1, hvor trin b) endvidere omfatter: b') vask af det bundne Fc-fusionsprotein med en buffer med et pH, der ligger i intervallet fra 3 til 7, og en ledeevne i intervallet fra 10 ms/cm til 50 ms/cm.
- 4. Fremgangsmåde ifølge krav 1, hvor trin d) endvidere omfatter: d') vask af det bundne Fc-fusionsprotein med en buffer med et pH, der ligger i intervallet fra 3 til 7, og en ledeevne i intervallet fra 10 ms/cm til 50 ms/cm.
- 5. Fremgangsmåde ifølge krav 1, hvor elueringen i trin g) udføres med en 12,5 mM natriumphosphatbuffer, pH 8,0, som lineær ionisk styrkegradient.
- 6. Fremgangsmåde ifølge krav 1, hvor trin d) endvidere omfatter: d') vask af det bundne Fc-fusionsprotein med en buffer, der har et pH, der ligger i intervallet fra 3 til 7, og en ledeevne i intervallet fra 10 ms/cm til 50 ms/cm.
- 7. Fremgangsmåde ifølge krav 1, hvor Protein A kromatografiharpiksen er POROS MabCapture A.
- 8. Fremgangsmåde ifølge krav 1, hvor CEX-kromatografitrinnet udiøres på en kraftig kationbytterharpiks, der er udvalgt fra Poros HS, Poros XS, SP Sepharose, Toyopearl SP, SP Sepharose BB, Source 30S, TSKGel SP-5PW-HR20 og Toyopearl SP 650, og AEX-kromatografitrinnet udføres på en kraftig anionbytterharpiks, der er udvalgt fra Poros HQ, Q-Sepharose, Q-Ceramic Hyper D, Toyopearl Q, UNO Q.
- 9. Fremgangsmåde ifølge krav 8, hvor CEX-kromatografiharpikser er Poros HS kraftig kationbytterharpiks og AEX kromatografiharpiksen er Poros HQ kraftig anionbytterharpiks.
- 10. Fremgangsmåde ifølge krav 1, hvor prøven, der omfatter Fc-fusionsproteinet, er pattedyrecelledyrkningsbouillon eller gærfermenteringsbouillon.
- 11. Fremgangsmåde ifølge krav 10, hvor prøven, der omfatter Fc-fusionsproteinet, er gærfermenteringsbouillon og trin a) endvidere omfatter: a') justering af pFI’et for prøven, der omfatter Fc-fusionsproteinet, til et pH mellem 8 til 9, og etablering af kontakt mellem prøven og et genfoldningsmidlet og et disaggregeringsmiddel.
- 12. Fremgangsmåde ifølge krav 11, hvor genfoldningsmidlet er udvalgt fra arginin, glycerol, EDTA, TMAO, PEG-3500 eller en redox-reagens og disaggregeringsmidlet er udvalgt fra urea eller guanidinhydrochlorid.
- 13. Fremgangsmåde ifølge krav 11, hvor pH’et for den prøve, der omfatter Fc-fusionsproteinet, justeres til 8,6.
- 14. Fremgangsmåde ifølge krav 1, hvor den oprensede Fc-fusionsproteinsammensætning opnået i trin g) tilvejebringer et produkt med en renhed på > 99 %.
- 15. Fremgangsmåde ifølge krav 1, hvor den oprensede Fc-fusionsproteinsammensætning, der er opnået i trin g), er kendetegnet ved et TSA-niveau på > 18 mMol.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161505710P | 2011-07-08 | 2011-07-08 | |
| PCT/US2012/045339 WO2013009526A1 (en) | 2011-07-08 | 2012-07-03 | Method for purifying fc-fusion protein |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2729482T3 true DK2729482T3 (da) | 2018-05-07 |
Family
ID=47506409
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK12811874.2T DK2729482T3 (da) | 2011-07-08 | 2012-07-03 | Fremgangsmåde til oprensning af fc-fusionsprotein |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9556258B2 (da) |
| EP (1) | EP2729482B1 (da) |
| JP (1) | JP6280499B2 (da) |
| KR (1) | KR20140043934A (da) |
| CN (1) | CN103814044A (da) |
| AU (2) | AU2012282960A1 (da) |
| BR (1) | BR112014000352A2 (da) |
| CA (1) | CA2840951A1 (da) |
| DK (1) | DK2729482T3 (da) |
| WO (1) | WO2013009526A1 (da) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112014009146A8 (pt) | 2011-10-18 | 2017-06-20 | Coherus Biosciences Inc | formulações de etanercepte estabilizadas com aminoácidos |
| SI2895188T1 (en) | 2012-09-11 | 2018-05-31 | Coherus Biosciences, Inc. | CORRECTED QUALITY ETHANERCEPT WITH HIGH QUALITY AND EXCELLENT EXPERIENCE |
| SI3395423T1 (sl) | 2013-03-14 | 2023-12-29 | Amgen Inc. | Odstranjevanje izluženega liganda za afinitetno čiščenje |
| SG10201802023RA (en) * | 2013-03-26 | 2018-05-30 | Coherus Biosciences Inc | Protein production method |
| WO2015120056A1 (en) * | 2014-02-04 | 2015-08-13 | Biogen Ma Inc. | Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications |
| PL3137209T3 (pl) | 2014-05-02 | 2023-01-02 | W.R. Grace & Co. - Conn. | Funkcjonalizowany materiał nośnikowy i sposoby wytwarzania oraz stosowania funkcjonalizowanego materiału nośnikowego |
| EP4218991A1 (en) | 2014-05-13 | 2023-08-02 | Amgen Inc. | Process control systems and methods for use with filters and filtration processes |
| MX2016016318A (es) * | 2014-06-13 | 2017-06-12 | Lupin Atlantis Holdings Sa | Proceso para la purificacion de la proteina de fusion. |
| FR3025515B1 (fr) * | 2014-09-05 | 2016-09-09 | Lab Francais Du Fractionnement | Procede de purification d'un anticorps monoclonal |
| WO2016065273A1 (en) * | 2014-10-24 | 2016-04-28 | The University Of Chicago | Heat-inducible self-assembling protein domains |
| US20160130324A1 (en) | 2014-10-31 | 2016-05-12 | Shire Human Genetic Therapies, Inc. | C1 Inhibitor Fusion Proteins and Uses Thereof |
| US11566082B2 (en) | 2014-11-17 | 2023-01-31 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
| EP3241849A4 (en) | 2014-12-31 | 2018-06-20 | LG Chem, Ltd. | Method for producing tnfr-fc fusion protein containing target content of impurities |
| KR102566292B1 (ko) * | 2015-06-05 | 2023-08-10 | 더블유.알. 그레이스 앤드 캄파니-콘. | 흡착성 바이오프로세싱 정화제와 이의 제조 및 사용 방법 |
| EP3699269A1 (en) | 2015-09-22 | 2020-08-26 | F. Hoffmann-La Roche AG | Expression of fc-containing proteins |
| US20170101435A1 (en) * | 2015-10-13 | 2017-04-13 | Therapeutic Proteins International, LLC | Harvesting and perfusion apparatus |
| CN108463243B (zh) | 2015-11-19 | 2022-06-14 | 夏尔人类遗传性治疗公司 | 重组人c1酯酶抑制剂及其用途 |
| WO2017194592A1 (en) | 2016-05-11 | 2017-11-16 | Ge Healthcare Bioprocess R&D Ab | Method of storing a separation matrix |
| US10703774B2 (en) | 2016-09-30 | 2020-07-07 | Ge Healthcare Bioprocess R&D Ab | Separation method |
| US10889615B2 (en) | 2016-05-11 | 2021-01-12 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
| JP7031934B2 (ja) | 2016-05-11 | 2022-03-08 | サイティバ・バイオプロセス・アールアンドディ・アクチボラグ | 分離マトリックス |
| WO2017194593A1 (en) | 2016-05-11 | 2017-11-16 | Ge Healthcare Bioprocess R&D Ab | Method of cleaning and/or sanitizing a separation matrix |
| US10730908B2 (en) | 2016-05-11 | 2020-08-04 | Ge Healthcare Bioprocess R&D Ab | Separation method |
| US10654887B2 (en) | 2016-05-11 | 2020-05-19 | Ge Healthcare Bio-Process R&D Ab | Separation matrix |
| US10513537B2 (en) | 2016-05-11 | 2019-12-24 | Ge Healthcare Bioprocess R&D Ab | Separation matrix |
| KR102579850B1 (ko) * | 2016-07-22 | 2023-09-18 | 암젠 인크 | Fc-함유 단백질의 정제 방법 |
| US12448411B2 (en) | 2016-09-30 | 2025-10-21 | Cytiva Bioprocess R&D Ab | Separation method |
| CN109929038B (zh) * | 2017-12-15 | 2020-10-09 | 山东博安生物技术有限公司 | Vegf捕获剂融合蛋白的纯化方法 |
| CN109929027B (zh) * | 2017-12-15 | 2020-10-09 | 山东博安生物技术有限公司 | 采用线性洗脱步骤的重组融合蛋白纯化方法 |
| EP3941607A1 (en) * | 2019-03-21 | 2022-01-26 | Codiak BioSciences, Inc. | Process for preparing extracellular vesicles |
| IL292940A (en) * | 2019-11-22 | 2022-07-01 | Morphosys Ag | Collection of extractant during antibody chromatography |
| AU2021262609A1 (en) | 2020-05-01 | 2022-12-22 | Kashiv Biosciences, Llc | An improved process of purification of protein |
| US11416468B2 (en) * | 2020-07-21 | 2022-08-16 | International Business Machines Corporation | Active-active system index management |
| CN112574321B (zh) * | 2020-12-30 | 2023-10-20 | 上海赛金生物医药有限公司 | 一种捕获单克隆抗体-肿瘤坏死因子融合蛋白的亲和纯化方法 |
| EP4291246A4 (en) * | 2021-02-11 | 2024-12-11 | Denali Therapeutics Inc. | ANTI-TRANSFERRIN RECEPTOR FUSION PROTEINS AND METHODS OF USE THEREOF |
| US20240400612A1 (en) * | 2021-09-28 | 2024-12-05 | Kashiv Biosciences, Llc | An improved process for purification of fusion protein |
| AU2022358612A1 (en) * | 2021-09-28 | 2024-04-11 | Kashiv Biosciences, Llc | An improved process of purification of fusion protein |
| CN114891061A (zh) * | 2022-04-25 | 2022-08-12 | 杭州艾策生物技术有限公司 | 一种糖基化重组蛋白的纯化方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU5927398A (en) * | 1997-01-21 | 1998-08-07 | Human Genome Sciences, Inc. | Fc receptors and polypeptides |
| EP1006183A1 (en) * | 1998-12-03 | 2000-06-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Recombinant soluble Fc receptors |
| ES2322945T5 (es) * | 2001-12-21 | 2012-10-17 | Immunex Corporation | Métodos para purficación de proteína |
| EP1543106B1 (en) * | 2002-07-15 | 2007-04-11 | Immunex Corporation | Methods and media for controlling sialylation of proteins produced by mammalian cells |
| GB0304576D0 (en) | 2003-02-28 | 2003-04-02 | Lonza Biologics Plc | Protein a chromatography |
| US7427659B2 (en) | 2003-10-24 | 2008-09-23 | Amgen Inc. | Process for purifying proteins in a hydrophobic interaction chromatography flow-through fraction |
| US20090105455A1 (en) * | 2004-04-14 | 2009-04-23 | Andreas Herrmann | Purified interleukin-15/fc fusion protein and preparation thereof |
| JP2010501622A (ja) * | 2006-08-28 | 2010-01-21 | アレス トレーディング ソシエテ アノニム | Fc−融合タンパク質の精製法 |
| WO2008025747A1 (en) * | 2006-08-28 | 2008-03-06 | Ares Trading S.A. | Process for the purification of fc-fusion proteins |
| WO2008085988A1 (en) * | 2007-01-05 | 2008-07-17 | Amgen Inc. | Methods of purifying proteins |
| SG177202A1 (en) * | 2008-09-15 | 2012-01-30 | Emd Millipore Corp | Methods for quantifying protein leakage from protein based affinity chromatography resins |
| US20120282654A1 (en) | 2009-04-29 | 2012-11-08 | Schering Corporation | Antibody purification |
| EP2462157B1 (en) * | 2009-08-07 | 2020-06-17 | EMD Millipore Corporation | Methods for purifying a target protein from one or more impurities in a sample |
| US9540426B2 (en) * | 2009-10-06 | 2017-01-10 | Bristol-Myers Squibb Company | Mammalian cell culture processes for protein production |
-
2012
- 2012-07-03 DK DK12811874.2T patent/DK2729482T3/da active
- 2012-07-03 BR BR112014000352A patent/BR112014000352A2/pt not_active IP Right Cessation
- 2012-07-03 AU AU2012282960A patent/AU2012282960A1/en not_active Abandoned
- 2012-07-03 US US14/131,280 patent/US9556258B2/en not_active Expired - Fee Related
- 2012-07-03 KR KR1020147002981A patent/KR20140043934A/ko not_active Withdrawn
- 2012-07-03 EP EP12811874.2A patent/EP2729482B1/en not_active Not-in-force
- 2012-07-03 CA CA2840951A patent/CA2840951A1/en not_active Abandoned
- 2012-07-03 JP JP2014519246A patent/JP6280499B2/ja not_active Expired - Fee Related
- 2012-07-03 CN CN201280043885.2A patent/CN103814044A/zh active Pending
- 2012-07-03 WO PCT/US2012/045339 patent/WO2013009526A1/en not_active Ceased
-
2017
- 2017-07-14 AU AU2017204893A patent/AU2017204893A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2012282960A1 (en) | 2014-01-16 |
| BR112014000352A2 (pt) | 2017-02-14 |
| CA2840951A1 (en) | 2013-01-17 |
| EP2729482A4 (en) | 2015-02-25 |
| US9556258B2 (en) | 2017-01-31 |
| JP6280499B2 (ja) | 2018-02-14 |
| WO2013009526A1 (en) | 2013-01-17 |
| EP2729482A1 (en) | 2014-05-14 |
| AU2017204893A1 (en) | 2017-08-03 |
| KR20140043934A (ko) | 2014-04-11 |
| EP2729482B1 (en) | 2018-03-07 |
| US20140187751A1 (en) | 2014-07-03 |
| CN103814044A (zh) | 2014-05-21 |
| JP2014520814A (ja) | 2014-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2729482T3 (da) | Fremgangsmåde til oprensning af fc-fusionsprotein | |
| US11459374B2 (en) | Anti-VEGF protein compositions and methods for producing the same | |
| AU2011284896B2 (en) | Protein purification | |
| US20140288278A1 (en) | Chromatography process for resolving heterogeneous antibody aggregates | |
| CN107636005B (zh) | 在色谱过程中利用碱洗涤去除杂质 | |
| AU2012283858C1 (en) | Polypeptide separation methods | |
| TW201444863A (zh) | 增加蛋白質之焦-麩胺酸形成的方法 | |
| CA3214610A1 (en) | Purification of antibodies by mixed mode chromatography | |
| HK40096315A (zh) | 通过混合模式色谱纯化抗体 |